Insider Selling: Infinity Pharmaceuticals CEO Unloads 45,000 Shares of Stock (INFI)
Infinity Pharmaceuticals (NASDAQ:INFI) CEO Adelene Perkins sold 45,000 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $20.72, for a total value of $932,400.00. Following the completion of the transaction, the chief executive officer now directly owns 447,535 shares in the company. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Morgan Stanley cut their price target on shares of Infinity Pharmaceuticals (NASDAQ:INFI) from $47.00 to $25.00 in a research note to investors on Monday, August 19th. They now have a “hold” rating on the stock. Analysts at Goldman Sachs Group Inc. cut their price target on shares of Infinity Pharmaceuticals (NASDAQ:INFI) from $40.00 to $20.00 in a research note to investors on Friday, July 5th. They now have a “neutral” rating on the stock.
Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $33.57.
Infinity Pharmaceuticals (NASDAQ:INFI) traded up 0.88% during mid-day trading on Friday, hitting $20.882. The stock had a trading volume of 327,220 shares. Infinity Pharmaceuticals has a one year low of $15.45 and a one year high of $50.51. The stock’s 50-day moving average is $19.99 and its 200-day moving average is $28.92. The company’s market cap is $1.002 billion.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings data on Thursday, August 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.06. During the same quarter in the previous year, the company posted ($0.54) earnings per share. On average, analysts predict that Infinity Pharmaceuticals will post $-2.90 earnings per share for the current fiscal year.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.